They also said that treatments customized to each patient, (e.g., an anti-idiotypic antibody treatment for B cell lymphoma that targets the specific B cell causing a patient's lymphoma,) tends to work better, but is much more expensive and technically difficult to accomplish than a one-size fits all treatment (like the anti-CD20 antibody Rituxan.)
I don't follow them closely but isn't that what Favrille is doing? Not sure where they stand now but a couple months ago they had a big setback. I seem to recall another company in a similar stage (Phase 2 or 3) working on something similar too but can't recall who.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.